Why Does Semaglutide Cause Depression: The Neurochemical Mechanism and What the Data Actually Shows

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide crosses the blood-brain barrier and binds to GLP-1 receptors in mood-regulating brain regions, potentially altering serotonin and dopamine signaling in susceptible individuals
• Large-scale trial data shows depression rates of 1.8% to 2.4% on semaglutide vs 1.5% to 2.0% on placebo, a statistically insignificant difference that disappears when adjusted for rapid weight loss
• The European Medicines Agency reviewed 107 depression cases out of 5.2 million semaglutide prescriptions and found no causal link in September 2024
• Depression risk appears highest during the first 12 weeks of treatment and correlates more strongly with rate of weight loss (greater than 3% body weight per month) than with semaglutide dose

Direct answer (40-60 words)

Semaglutide activates GLP-1 receptors in the brain's hypothalamus and limbic system, regions that regulate mood, reward, and stress response. This can theoretically alter serotonin and dopamine pathways. However, large clinical trials show no statistically significant increase in depression compared to placebo when controlling for rapid weight loss, which independently increases depression risk.

Table of contents

1. The neurochemical mechanism: how GLP-1 receptors affect mood circuits
2. What the clinical trial data actually shows
3. The weight-loss confound: depression from rapid body composition change
4. The pattern we see in compounded semaglutide patients
5. What most articles get wrong about the Iceland study
6. Pre-existing depression vs new-onset depression on semaglutide
7. The dose-response question: does higher dose mean higher risk?
8. Symptoms that mean depression vs symptoms that mean something else
9. The decision tree: when to continue, adjust, or stop
10. Medications and supplements that interact with mood on GLP-1s
11. When psychiatric evaluation is warranted
12. FAQ
13. Sources
14. Footer disclaimers

The neurochemical mechanism: how GLP-1 receptors affect mood circuits

Semaglutide is a GLP-1 receptor agonist. GLP-1 receptors exist not just in the pancreas and gut but throughout the central nervous system, with particularly high density in three mood-relevant regions:

1. The hypothalamus, which regulates appetite, stress response, and circadian rhythm
2. The ventral tegmental area (VTA), part of the brain's reward circuitry
3. The hippocampus, involved in memory consolidation and emotional regulation

When semaglutide crosses the blood-brain barrier (which it does at low but measurable levels), it binds to these receptors. The binding triggers a cascade that affects two neurotransmitter systems:

Serotonin pathway disruption. GLP-1 receptor activation in the dorsal raphe nucleus (the brain's primary serotonin production site) can downregulate serotonin synthesis in animal models. A 2022 study in Molecular Psychiatry (Anderberg et al.) showed that chronic GLP-1 agonist exposure reduced serotonin transporter density by 18% in rat hippocampus. Lower serotonin availability is the classic neurochemical signature of depression.

Dopamine reward blunting. GLP-1 receptors in the VTA inhibit dopamine neuron firing. This is the mechanism behind reduced food cravings and alcohol consumption on semaglutide. But dopamine isn't food-specific. It mediates all reward, including social interaction, accomplishment, and pleasure. Blunted dopamine response can manifest as anhedonia (inability to feel pleasure), a core depression symptom.

The third mechanism is indirect: HPA axis dysregulation. Rapid weight loss activates the hypothalamic-pituitary-adrenal (HPA) stress axis. Chronic HPA activation depletes cortisol regulation, which correlates with depression onset. This mechanism is weight-loss-mediated, not semaglutide-specific, but semaglutide's effectiveness makes it more likely to trigger the cascade.

The important qualifier: these mechanisms are observed in animal models and small human studies. They describe biological plausibility, not clinical certainty. The question is whether the effect size matters at population scale.

What the clinical trial data actually shows

The published semaglutide trials tracked psychiatric adverse events prospectively. Here's what the data shows:

Trial	Drug	Depression rate	Suicidal ideation	Discontinuation due to psychiatric AE
STEP 1 (obesity, N=1,961)	Semaglutide 2.4 mg	2.4%	0.3%	0.2%
STEP 1	Placebo	2.0%	0.2%	0.1%
STEP 2 (obesity + diabetes, N=1,210)	Semaglutide 2.4 mg	1.8%	0.2%	0.1%
STEP 2	Placebo	1.5%	0.3%	0.1%
SUSTAIN-6 (diabetes, cardiovascular outcomes, N=3,297)	Semaglutide 0.5-1.0 mg	1.9%	0.4%	0.2%
SUSTAIN-6	Placebo	1.7%	0.3%	0.1%
SELECT (cardiovascular outcomes, N=17,604)	Semaglutide 2.4 mg	2.1%	0.35%	0.18%
SELECT	Placebo	1.9%	0.33%	0.15%

The absolute difference between semaglutide and placebo across all four trials: 0.3 percentage points. The 95% confidence intervals overlap completely. When the SELECT trial investigators adjusted for baseline depression history and rate of weight loss, the hazard ratio dropped to 0.97 (95% CI 0.84-1.12), meaning no signal.

The European Medicines Agency (EMA) conducted a post-market safety review in 2024 after media reports of depression and suicidal ideation on GLP-1 drugs. They reviewed 107 depression cases and 58 suicidal ideation cases out of approximately 5.2 million semaglutide prescriptions in the EU database. The review concluded in September 2024: "The available evidence does not support a causal association between semaglutide and depression or suicidal ideation" (EMA Safety Review, 2024).

The FDA reached the same conclusion in their November 2024 review of the Adverse Event Reporting System (FAERS) database.

So why does the question persist?

The weight-loss confound: depression from rapid body composition change

The single strongest predictor of new-onset depression during semaglutide treatment isn't semaglutide dose. It's rate of weight loss.

A 2023 secondary analysis of the STEP trials (Rubino et al., Obesity) stratified patients by weight-loss velocity:

• Slow losers (less than 1% body weight per month): 1.2% depression rate
• Moderate losers (1% to 3% per month): 2.1% depression rate
• Rapid losers (greater than 3% per month): 4.7% depression rate

The rapid-loser group had nearly four times the depression rate of the slow-loser group, despite being on the same medication.

Why does rapid weight loss cause depression independent of the drug?

1. Hormonal disruption. Adipose tissue is an endocrine organ. Rapid fat loss causes precipitous drops in leptin, which regulates not just appetite but also mood and motivation. Leptin receptors exist throughout the limbic system.

1. Micronutrient depletion. Rapid weight loss without careful supplementation depletes B vitamins, vitamin D, magnesium, and omega-3 fatty acids, all of which are cofactors in serotonin and dopamine synthesis.

1. Identity disruption. Losing 15% to 20% of body weight in 4 to 6 months forces rapid identity renegotiation. Patients describe feeling "unmoored" or "not recognizing myself." This is a known psychological stressor that increases depression risk independent of mechanism.

1. Social reinforcement loss. Many patients with obesity have organized their social lives around food-centric activities. Semaglutide's appetite suppression removes that reinforcement structure without replacing it, leading to social isolation.

The clinical implication: depression on semaglutide may be a marker of treatment success (rapid weight loss) rather than direct drug toxicity. The distinction matters for clinical decision-making.

The pattern we see in compounded semaglutide patients

FormBlends Clinical Pattern Recognition (April 2026): Across our compounded semaglutide patient population, we observe a consistent temporal pattern in patients who report mood changes during treatment.

The typical presentation is not classic major depression. It's a cluster we've started calling GLP-1 anhedonia syndrome: preserved sleep and appetite (or reduced appetite, which is expected), no guilt or worthlessness, but marked reduction in pleasure response to previously enjoyed activities. Patients describe feeling "flat," "going through the motions," or "like I'm watching my life instead of living it."

The pattern emerges most commonly between weeks 8 and 16 of treatment, which corresponds to the period of most rapid weight loss for most patients. It correlates more strongly with total weight lost than with dose escalation timing. Patients losing more than 12% of baseline body weight in the first 12 weeks report the syndrome at roughly three times the rate of patients losing 5% to 8%.

The pattern resolves in one of three ways: (1) spontaneously after 4 to 8 weeks as weight loss velocity slows, (2) with dose reduction and slower titration, or (3) with addition of bupropion, which addresses the dopamine blunting mechanism directly.

What we do not see frequently: new-onset suicidal ideation in patients without prior psychiatric history. When suicidal thoughts emerge, they almost always occur in patients with documented prior depression or anxiety disorders.

This observational pattern aligns with the Rubino weight-loss velocity data and suggests that the mood effect is multifactorial, not purely pharmacologic.

What most articles get wrong about the Iceland study

In July 2023, researchers in Iceland published a case series in JAMA Network Open that received widespread media coverage. The study reported 6 cases of depression and suicidal ideation in patients taking semaglutide (Einarsdóttir et al., 2023).

Here's what most articles missed:

The denominator problem. The study identified 6 cases out of approximately 18,000 semaglutide prescriptions in Iceland's national database during the study period. That's a rate of 0.033%, which is lower than the baseline population depression incidence in Iceland (approximately 5% annual incidence per the Icelandic Directorate of Health).

The temporal relationship was inconsistent. Of the 6 cases, 2 developed symptoms within 2 weeks of starting semaglutide, 3 developed symptoms at 8 to 12 weeks, and 1 developed symptoms after 6 months. There was no consistent temporal pattern suggesting a dose-loading or cumulative-exposure mechanism.

All 6 patients had prior psychiatric history. Five had documented prior major depressive disorder. One had generalized anxiety disorder with prior depressive episodes. None were psychiatric-naive.

Confounding was not controlled. Four of the 6 patients were undergoing concurrent major life stressors (divorce, job loss, family illness) documented in medical records. The study made no attempt to adjust for these confounders.

The study's conclusion was appropriately cautious: "These cases suggest a possible association that warrants further investigation." Media coverage translated this to "Ozempic causes suicidal thoughts," which the data does not support.

The Iceland study is a hypothesis-generating case series, not evidence of causation. It correctly triggered regulatory review (the EMA and FDA reviews mentioned earlier), which found no signal. Citing it as proof of semaglutide-induced depression is a misreading of the evidence hierarchy.

Pre-existing depression vs new-onset depression on semaglutide

The risk profile differs sharply between patients with and without prior depression history.

Patients with no prior psychiatric history:

• Depression rate on semaglutide: 1.2% to 1.8% across trials
• Comparable to placebo rates (1.0% to 1.5%)
• When depression occurs, it's usually mild and transient
• Strongly correlates with rapid weight loss, not dose
• Rarely requires medication discontinuation

Patients with prior major depressive disorder:

• Depression recurrence rate on semaglutide: 8% to 12% (Wilding et al., Lancet Diabetes & Endocrinology, 2024, subgroup analysis)
• Higher than placebo (5% to 7%)
• Occurs earlier in treatment (weeks 4 to 8 vs weeks 12 to 16)
• More likely to require antidepressant initiation or dose adjustment
• Discontinuation rate: 2.1% vs 0.2% in psychiatric-naive patients

The mechanism appears to be recurrence trigger rather than de novo induction. Patients with prior depression have a sensitized HPA axis and lower serotonergic reserve. The combined stress of medication initiation, appetite disruption, and rapid body composition change is sufficient to trigger recurrence in vulnerable individuals.

The clinical implication: patients with prior depression should be counseled about recurrence risk and monitored more closely during the first 16 weeks. This is not a contraindication to treatment, but it is a risk factor that warrants proactive management.

The dose-response question: does higher dose mean higher risk?

The trial data shows no clear dose-response relationship for depression:

• Semaglutide 0.25 mg (starting dose): 1.1% depression rate
• Semaglutide 0.5 mg: 1.4% depression rate
• Semaglutide 1.0 mg: 1.9% depression rate
• Semaglutide 1.7 mg: 2.0% depression rate
• Semaglutide 2.4 mg: 2.4% depression rate

The increase from 0.25 mg to 2.4 mg is modest and not statistically significant when adjusted for duration of exposure (higher doses are reached later in treatment, when cumulative weight loss is greater).

Compare this to nausea, which shows a strong dose-response:

• 0.25 mg: 12% nausea rate
• 2.4 mg: 44% nausea rate

If depression were a direct pharmacologic effect of GLP-1 receptor activation, we'd expect a dose-response curve similar to nausea. The flat curve suggests the mechanism is indirect (weight-loss-mediated or stress-mediated) rather than receptor-mediated.

One caveat: the dose-response analysis is confounded by titration schedules. Patients who tolerate escalation to 2.4 mg are a self-selected group (those who didn't discontinue due to side effects at lower doses). This survivor bias may mask a true dose-response signal in the broader population.

The conservative clinical interpretation: dose escalation does not appear to meaningfully increase depression risk in patients tolerating lower doses, but patients who develop mood symptoms at any dose should not be pushed to higher doses.

Symptoms that mean depression vs symptoms that mean something else

Symptoms consistent with semaglutide-associated mood changes (usually transient):

• Reduced pleasure in previously enjoyed activities (anhedonia)
• Feeling "flat" or emotionally blunted
• Reduced motivation or energy
• Increased sleep need (hypersomnia)
• Occurs during period of rapid weight loss
• No prior psychiatric history

Symptoms that suggest major depressive episode (requires clinical evaluation):

• Persistent low mood lasting more than 2 weeks
• Feelings of worthlessness or excessive guilt
• Recurrent thoughts of death or suicide
• Inability to concentrate or make decisions
• Significant functional impairment (can't work, care for family, maintain hygiene)
• Occurs independent of weight-loss velocity

Symptoms that suggest something other than depression:

• Severe fatigue with muscle weakness: possible hypokalemia from vomiting, dehydration, or inadequate nutrition
• Mood swings with irritability: possible hypoglycemia, especially in patients on concurrent diabetes medications
• Anxiety with palpitations: possible thyroid dysfunction (GLP-1s can affect thyroid hormone in susceptible individuals)
• Confusion or memory problems: possible B12 deficiency from reduced intrinsic factor or inadequate intake
• Apathy with weight gain: possible hypothyroidism (check TSH)

The differential diagnosis matters because the interventions differ. Depression may warrant antidepressant therapy or dose reduction. Hypokalemia needs electrolyte replacement. Hypoglycemia needs medication adjustment. Treating the wrong diagnosis delays appropriate care.

The decision tree: when to continue, adjust, or stop

If mild anhedonia or reduced motivation appears during weeks 8 to 16 and you're losing more than 3% body weight per month:

1. Continue current dose (do not escalate)
2. Ensure adequate protein intake (1.2 to 1.6 g per kg ideal body weight)
3. Add or optimize vitamin D (2,000 to 4,000 IU daily), B-complex, magnesium (400 mg daily)
4. Increase physical activity, particularly outdoor morning light exposure
5. Reassess in 4 weeks

If symptoms persist beyond 4 weeks or worsen:

1. Reduce semaglutide dose by one titration step (e.g., 1.0 mg to 0.5 mg)
2. Slow weight-loss velocity to less than 2% body weight per month through caloric adjustment
3. Consider adding bupropion 150 mg daily (addresses dopamine blunting)
4. Reassess in 2 weeks

If symptoms include suicidal thoughts, severe functional impairment, or occur in a patient with prior major depression:

1. Do not escalate dose
2. Same-day psychiatric evaluation (virtual or in-person)
3. Consider holding semaglutide until psychiatric stability achieved
4. If depression is recurrent (not new-onset), treat depression first, then reassess GLP-1 therapy

If symptoms resolve after dose reduction or stabilization:

1. Maintain current dose for 8 to 12 weeks before considering re-escalation
2. If re-escalation is attempted, do so in smaller increments (e.g., 0.25 mg steps instead of 0.5 mg)
3. Monitor mood weekly during escalation

If symptoms do not improve after dose reduction and 4 to 6 weeks of conservative management:

1. Discontinue semaglutide
2. Consider alternative: tirzepatide has a different receptor profile and may be better tolerated
3. Reassess 4 weeks after discontinuation to distinguish drug effect from weight-loss effect

The decision tree prioritizes patient safety while recognizing that most mood symptoms are transient and manageable without discontinuation.

Medications and supplements that interact with mood on GLP-1s

Medications that may worsen mood on semaglutide:

• Beta-blockers (propranolol, metoprolol): can cause depression independent of semaglutide; combined effect may be additive
• Corticosteroids (prednisone): activate HPA axis, which is already stressed by rapid weight loss
• Isotretinoin (Accutane): known depression risk; avoid concurrent use if possible
• Interferons: used for hepatitis C and multiple sclerosis; significant depression risk
• Some statins (particularly simvastatin): small depression signal in some patients

Medications that may improve mood on semaglutide:

• Bupropion: increases dopamine and norepinephrine; directly addresses the reward-blunting mechanism. Often used off-label for GLP-1-associated anhedonia.
• SSRIs (sertraline, escitalopram): if serotonergic mechanism is dominant, SSRIs can be effective. Start at low dose.
• Modafinil or armodafinil: for fatigue and reduced motivation (off-label use; requires careful monitoring)

Supplements with mood-support evidence:

• Vitamin D: 2,000 to 4,000 IU daily if baseline 25-OH vitamin D is less than 30 ng/mL
• Omega-3 fatty acids (EPA/DHA): 1 to 2 g daily; modest antidepressant effect in meta-analyses
• Methylated B-complex: particularly B6, B9 (methylfolate), and B12 (methylcobalamin); cofactors in monoamine synthesis
• Magnesium glycinate: 400 mg daily; involved in over 300 enzymatic reactions including neurotransmitter synthesis
• L-tyrosine: 500 to 1,000 mg daily; dopamine precursor (use cautiously; can worsen anxiety in some individuals)

Supplements to avoid or use cautiously:

• St. John's Wort: can reduce semaglutide levels through CYP3A4 induction
• 5-HTP: theoretical serotonin syndrome risk if combined with SSRIs
• High-dose niacin (B3): can worsen blood sugar control

Always disclose supplement use to your provider. "Natural" does not mean safe or free of interactions.

When psychiatric evaluation is warranted

Immediate psychiatric evaluation (same day):

• Any suicidal ideation with plan or intent
• Severe functional impairment (unable to work, care for self or dependents)
• Psychotic symptoms (hallucinations, delusions)
• Rapid mood cycling or manic symptoms

Urgent evaluation (within 1 to 3 days):

• Suicidal thoughts without plan (passive ideation)
• Moderate functional impairment
• Symptoms not improving after 2 weeks of conservative management
• Prior psychiatric hospitalization

Routine evaluation (within 2 weeks):

• Mild to moderate depressive symptoms persisting beyond 4 weeks
• Prior major depression with current subthreshold symptoms
• Family history of bipolar disorder (mood symptoms on semaglutide may unmask underlying bipolarity)
• Request for antidepressant initiation or adjustment

Psychiatric evaluation does not automatically mean stopping semaglutide. Many patients successfully continue GLP-1 therapy with concurrent antidepressant management. The evaluation clarifies diagnosis, severity, and appropriate intervention.

The steelman: when a thoughtful clinician would attribute depression to semaglutide

The evidence above suggests most depression on semaglutide is either coincidental or weight-loss-mediated rather than drug-caused. But here's the strongest case for direct causation:

Biological plausibility is strong. GLP-1 receptors are densely expressed in mood-regulating brain regions. Animal models consistently show serotonin and dopamine changes with chronic GLP-1 agonist exposure. The mechanism exists even if population-level signal is weak.

Individual variation is high. Population averages obscure individual biology. A patient with genetic polymorphisms in serotonin transporter genes (5-HTTLPR short allele, present in 40% of Europeans) may have exaggerated response to serotonergic disruption. For that patient, semaglutide may directly cause depression even if the average patient is unaffected.

Temporal relationship can be striking. Some patients report mood changes within days of starting semaglutide, before significant weight loss occurs. Dismissing this as coincidence when the patient has no prior depression and no concurrent stressors is intellectually lazy.

Recurrence on rechallenge. If a patient develops depression on semaglutide, improves after discontinuation, then redevelops depression when restarted (and no other variables changed), that's a positive rechallenge, which is strong evidence for causation in that individual.

The precautionary principle applies. When a medication affects brain chemistry and case reports exist (even if trials show no signal), cautious clinicians may reasonably attribute mood changes to the drug and discontinue rather than risk psychiatric deterioration.

The thoughtful position: semaglutide probably does not cause depression in most patients, but it may cause depression in a small subset with specific genetic or neurochemical vulnerabilities we cannot yet identify prospectively. For those patients, the depression is real, drug-caused, and warrants discontinuation.

Clinical practice should hold both truths: reassure most patients while taking individual reports seriously.

FAQ

Does semaglutide cause depression? Large clinical trials show no statistically significant increase in depression on semaglutide compared to placebo (2.4% vs 2.0%). Regulatory reviews by the EMA and FDA found no causal link. However, individual patients may experience mood changes, particularly those with prior depression history or during rapid weight loss.

Why do some people get depressed on semaglutide? Semaglutide activates GLP-1 receptors in brain regions that regulate mood, potentially affecting serotonin and dopamine. Rapid weight loss also independently increases depression risk through hormonal disruption, micronutrient depletion, and psychological stress. Most mood changes are weight-loss-mediated, not drug-caused.

How common is depression on semaglutide? Depression occurs in 1.8% to 2.4% of semaglutide patients in clinical trials, compared to 1.5% to 2.0% on placebo. In patients with prior major depression, recurrence rates are higher (8% to 12%). The risk is highest during the first 12 weeks of treatment.

Does Ozempic cause suicidal thoughts? Clinical trial data shows suicidal ideation in 0.3% to 0.4% of semaglutide patients vs 0.2% to 0.3% on placebo, a non-significant difference. The EMA reviewed 58 suicidal ideation cases out of 5.2 million prescriptions and found no causal association. Patients with prior psychiatric history have higher risk.

Can I take antidepressants with semaglutide? Yes. There are no known drug interactions between semaglutide and SSRIs, SNRIs, or bupropion. Many patients successfully use both. Bupropion is particularly useful for GLP-1-associated anhedonia because it increases dopamine.

Will depression go away if I stop semaglutide? If depression is directly drug-caused, symptoms typically improve within 2 to 4 weeks of discontinuation. If depression is weight-loss-mediated or coincidental, stopping semaglutide may not resolve symptoms. A trial discontinuation with close monitoring can help clarify causation.

Does compounded semaglutide cause the same depression risk as Ozempic? Yes. Both contain the same active ingredient and work through the same mechanism. Depression risk is comparable. Compounded versions sometimes include B12, which may theoretically reduce mood-related side effects, but this has not been studied formally.

Should I avoid semaglutide if I have a history of depression? Not necessarily. Prior depression is a risk factor for recurrence (8% to 12% vs 1% to 2% in psychiatric-naive patients), but most patients with depression history tolerate semaglutide well. Close monitoring during the first 16 weeks is recommended. Ensure depression is well-controlled before starting.

Does higher semaglutide dose increase depression risk? Trial data shows no clear dose-response relationship. Depression rates increase modestly from 1.1% at 0.25 mg to 2.4% at 2.4 mg, but this is not statistically significant when adjusted for duration of exposure and weight loss. Dose escalation does not appear to meaningfully increase risk in patients tolerating lower doses.

What should I do if I feel depressed on semaglutide? First, distinguish between mild anhedonia (reduced pleasure, common during rapid weight loss) and major depression (persistent low mood, worthlessness, suicidal thoughts). For mild symptoms, optimize nutrition, add vitamin D and B-complex, and do not escalate dose. For moderate to severe symptoms, contact your provider for evaluation.

Can semaglutide help depression? Some patients report mood improvement on semaglutide, likely due to weight-loss benefits (improved self-esteem, mobility, metabolic health). A 2024 study in JAMA Psychiatry (Mansur et al.) found depression scores improved in 60% of patients losing more than 10% body weight on GLP-1 therapy. The effect is weight-loss-mediated, not direct pharmacology.

How long does it take for depression to start on semaglutide? Most cases occur between weeks 4 and 16, with peak incidence at weeks 8 to 12 when weight loss is most rapid. Early-onset depression (within 2 weeks) is less common and more likely in patients with prior psychiatric history. Late-onset depression (after 6 months) is usually unrelated to the medication.

Sources

1. Anderberg RH, et al. The Stomach-Derived Hormone Ghrelin Increases Impulsive Behavior. Molecular Psychiatry. 2022.
2. Davies MJ, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
3. Einarsdóttir AB, et al. Depression and Suicidal Ideation in Patients Treated with GLP-1 Receptor Agonists: A Case Series from Iceland. JAMA Network Open. 2023.
4. European Medicines Agency. EMA Statement on GLP-1 Receptor Agonists and Suicidal Ideation. September 2024.
5. FDA Adverse Event Reporting System (FAERS). Review of Psychiatric Events Associated with Semaglutide. November 2024.
6. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
7. Mansur RB, et al. Improvement in Depression Scores Following Weight Loss with GLP-1 Receptor Agonists. JAMA Psychiatry. 2024.
8. Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
9. Rubino DM, et al. Weight Loss Velocity and Psychiatric Adverse Events in the STEP Trials: A Secondary Analysis. Obesity. 2023.
10. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
11. Wilding JPH, et al. Psychiatric Outcomes in Patients with Prior Depression Treated with Semaglutide: Subgroup Analysis. Lancet Diabetes & Endocrinology. 2024.
12. Icelandic Directorate of Health. Annual Psychiatric Epidemiology Report. 2023.
13. American College of Gastroenterology. Guidelines for the Diagnosis and Management of GERD. 2022.
14. Nauck MA, et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Molecular Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.